ATE483459T1 - Behandlung von überaktivität glatter muskulatur mit (r)-oxybutynin und (r)-desethyloxybutynin - Google Patents

Behandlung von überaktivität glatter muskulatur mit (r)-oxybutynin und (r)-desethyloxybutynin

Info

Publication number
ATE483459T1
ATE483459T1 AT00941235T AT00941235T ATE483459T1 AT E483459 T1 ATE483459 T1 AT E483459T1 AT 00941235 T AT00941235 T AT 00941235T AT 00941235 T AT00941235 T AT 00941235T AT E483459 T1 ATE483459 T1 AT E483459T1
Authority
AT
Austria
Prior art keywords
oxybutynin
smooth muscle
desethyloxybutynin
treating
optically pure
Prior art date
Application number
AT00941235T
Other languages
German (de)
English (en)
Inventor
A Aberg
Original Assignee
Watson Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Watson Pharmaceuticals Inc filed Critical Watson Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE483459T1 publication Critical patent/ATE483459T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT00941235T 2000-06-07 2000-06-07 Behandlung von überaktivität glatter muskulatur mit (r)-oxybutynin und (r)-desethyloxybutynin ATE483459T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/015515 WO2001093683A1 (en) 2000-06-07 2000-06-07 Treating smooth muscle hyperactivity with (r)-oxybutynin and (r)- desethyloxybutynin

Publications (1)

Publication Number Publication Date
ATE483459T1 true ATE483459T1 (de) 2010-10-15

Family

ID=21741461

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00941235T ATE483459T1 (de) 2000-06-07 2000-06-07 Behandlung von überaktivität glatter muskulatur mit (r)-oxybutynin und (r)-desethyloxybutynin

Country Status (9)

Country Link
EP (1) EP1286591B1 (enExample)
JP (1) JP5684964B2 (enExample)
CN (3) CN101108176A (enExample)
AT (1) ATE483459T1 (enExample)
AU (2) AU2000255966B2 (enExample)
CA (1) CA2378754A1 (enExample)
DE (1) DE60045082D1 (enExample)
ES (1) ES2350330T3 (enExample)
WO (1) WO2001093683A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002241721A1 (en) * 2001-12-21 2003-09-02 Bridge Pharma, Inc. A non-arrhythmogenic metabolite of oxybutynin
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
EP1629850B2 (en) * 2004-08-24 2013-05-22 N.V. Nutricia Nutritional composition comprising indigestible transgalactooligosaccharides and digestible galactose saccharides
US8920392B2 (en) 2009-05-05 2014-12-30 Watson Laboratories, Inc. Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
CN110152000A (zh) 2011-03-02 2019-08-23 J·深塔格 用于单独治疗肝脂肪变性或治疗伴有丙型肝炎病毒感染的肝脂肪变性的组合物
EP2714011B1 (en) 2011-06-03 2018-01-31 Signpath Pharma Inc. Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current
US12004868B2 (en) 2011-06-03 2024-06-11 Signpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel
US10117881B2 (en) 2011-06-03 2018-11-06 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
US10449193B2 (en) 2011-06-03 2019-10-22 Signpath Pharma Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies
US10349884B2 (en) 2011-06-03 2019-07-16 Sighpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
US10238602B2 (en) 2011-06-03 2019-03-26 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies
US20160151321A1 (en) 2012-11-13 2016-06-02 Dinesh C. Patel Methods for the treatment of sialorrhea
US20140135392A1 (en) * 2012-11-13 2014-05-15 NeuRx Pharmaceuticals LLC Methods for the treatment of sialorrhea
CN103169660B (zh) * 2013-04-15 2015-04-08 石正国 一种制备高包封率的利巴韦林脂质体口服乳
WO2015095576A1 (en) 2013-12-18 2015-06-25 Signpath Pharma, Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
EP3151837B1 (en) 2014-06-03 2023-03-15 Signpath Pharma, Inc. Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies
ES3014023T3 (en) 2016-04-27 2025-04-16 Signpath Pharma Inc Prevention of drug-induced atrio-ventricular block
IL297877A (en) 2020-05-05 2023-01-01 Apnimed Inc Delaware Polymorphic forms of (r)-oxybutynin hydrochloride
IL299572A (en) * 2020-07-03 2023-02-01 Phoxbio Ltd Reduction of viral infections

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4008269A (en) * 1970-05-05 1977-02-15 William H. Rorer, Inc. Phenylacetic acids
IT1231237B (it) * 1987-09-21 1991-11-26 Angeli Inst Spa Derivati eterociclici
US5677346A (en) * 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
US5973182A (en) * 1998-10-22 1999-10-26 Sepracor Inc. Carbonate Intermediates useful in the preparation of optically active cyclohexylphenylglycolate esters

Also Published As

Publication number Publication date
ES2350330T3 (es) 2011-01-21
CA2378754A1 (en) 2001-12-13
AU2000255966B2 (en) 2005-03-24
CN101108176A (zh) 2008-01-23
AU5596600A (en) 2001-12-17
EP1286591B1 (en) 2010-10-06
CN1454054A (zh) 2003-11-05
AU2000255966A1 (en) 2002-03-07
JP2003535110A (ja) 2003-11-25
EP1286591A1 (en) 2003-03-05
WO2001093683A1 (en) 2001-12-13
CN1451388A (zh) 2003-10-29
DE60045082D1 (de) 2010-11-18
EP1286591A4 (en) 2007-04-04
JP5684964B2 (ja) 2015-03-18

Similar Documents

Publication Publication Date Title
ATE483459T1 (de) Behandlung von überaktivität glatter muskulatur mit (r)-oxybutynin und (r)-desethyloxybutynin
CA2451474A1 (en) Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (mtp) and/or apolipoprotein b (apo b) secretion
AU2001283963A1 (en) Polysiloxane polymers, method for their production and the use thereof
AU2001249091A1 (en) Novel methods using cholinesterase inhibitors
DE60027769D1 (de) Pyrrolidin-derivate als inhibitoren von cyclischer amp-phosphodiesterase
NO20043038L (no) Polymorfe former av klopidogrel-hydrogensulfat
EP1862457A3 (en) Fluoropyrrolidines as dipeptidyl peptidase inhibitors
ATE292971T1 (de) (s,s)-reboxetin zur behandlung von peripheren neuropathien
EA200700116A1 (ru) Четвертичные соли, антагонисты ccr2
DK1202736T3 (da) Nikotin i terapeutisk angiogenese og vasculogenese
GEP20084325B (en) Purine compounds and uses thereof as cannabinoid receptor ligandspurine compounds and uses thereof as cannabinoid receptor ligands
AU2002366641A1 (en) Methods for inhibiting ocular processes
NO20054296D0 (no) Anvendelse av palonosetron for behandling av kvalme og oppkast etter kirurgisk inngrep
BR122018009866B8 (pt) métodos para preparar compostos de éter aminocicloexílico e compostos intermediários
CY1106409T1 (el) Παραγωγα κινολινης
WO2006050045A3 (en) Inhibitors of jun n-terminal kinases for treating glaucomatous retinopathy and ocular diseases
WO2003084928A8 (en) Alpha, omega-dicarboximide derivatives as useful uro-selective α1α adrenoceptor blockers
WO2003092611A3 (en) Methods of inducing formation of functional and organized lymphatic vessels
ATE278722T1 (de) Organische polymere
AU2001297649A1 (en) Tricyclic compounds and their analogs as inhibitors of cytokine signaling
NO20042138L (no) Forbindelser og fremgangsmate for behandling av hyperaktiv blaere
EP1152760A4 (en) USE OF 4-AMINOPYRIDINE FOR THE TREATMENT OF PERIPHERAL NEUROPATHIES
NZ511997A (en) Isonipecotamides for the treatment of integrin-mediated disorders
EP1233075A3 (en) BDNF polymorphism and association with bipolar disorder
WO2003045917A3 (en) Ccr-3 receptor antagonists vii

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties